GRN300–001: Phase 1/1B evaluation of the safety, pharmacokinetics, and efficacy of GRN-300, a salt-inducible kinase inhibitor, alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers.

paclitaxel - Generic mfg.

GRN300 - Greenfire Bio

Siqing Fu; Amir A. Jazaeri; Zhen Lu; Markus Peter; Stephan Wade Morris; Robert C. Bast

Apr 28, 2022